# Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19

> **NCT04386447** · PHASE2 · WITHDRAWN · sponsor: **Azienda Ospedaliero-Universitaria di Parma**

## Conditions studied

- Covid-19
- Corona Virus Infection
- SARS-CoV 2

## Interventions

- **DRUG:** Oxytocin
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT04386447
- **Lead sponsor:** Azienda Ospedaliero-Universitaria di Parma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09-01
- **Primary completion:** 2020-10-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was not approved by the Italian Medicines Agency (AIFA).
- **Last updated:** 2021-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04386447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04386447, "Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04386447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*